Tally Health

Market position

Positioned in the consumer longevity/AgeTech segment as a direct-to-consumer epigenetic testing and supplement brand. Its acquirer's stated rationale was that Tally's consumer brand and channel complement the largely B2B business of Infinite Epigenetics and TruDiagnostic, which serve research organizations, academia, payers and providers, creating a vertically integrated platform across diagnostics, data and consumer health.

The TallyAge Test is described as a next-generation epigenetic clock trained on what the company calls the largest adult cheek-swab DNA methylation dataset — over 8,000 diverse individuals aged 18 to 100 — using more than 200,000 genome-wide methylation sites, and delivered via a painless at-home buccal swab rather than a blood draw. The company also cites proprietary, exclusively licensed intellectual property and models derived from academic research, multi-ingredient supplement formulations built to defined evidence criteria, and personalized Action Plans that combine DNA and lifestyle data.

Technology

DNA methylation analysis of buccal (cheek) cells processed by lab partners, interpreted through the proprietary TallyAge epigenetic aging clock derived from the CheekAge model. In-house research covers explainable, AI-based epigenetic aging clocks, comparisons of first- versus next-generation clocks, clock divergence and noise correction across microarray and methylation sequencing technologies, and classifiers for lifestyle and demographic factors such as smoking status, BMI and alcohol intake from buccal methylomic data. Results and personalized recommendations are delivered through a digital member platform.

Go-to-market

Direct-to-consumer e-commerce and subscription sign-up on tallyhealth.com, supported by a content/newsletter program that translates aging research into consumer guidance, customer testimonials, celebrity investor association and press coverage. The company built an initial pipeline through a large pre-launch waitlist.

Consumers interested in longevity, biological age tracking and healthy aging. At launch the customer base skewed toward male biohackers; per the CEO, most subsequent growth has come from women making health decisions for themselves and their families, with the age range widening to roughly 30 to 60.

Geography

Announcements place Tally Health in New York; its acquirer, Infinite Epigenetics, is based in Lexington, Kentucky. Commentary from the company focuses on the U.S. market and the gap between lifespan and healthspan there.

History

The company launched in late February 2023 with a reported pre-launch waitlist of more than 270,000 people, and announced a $10 million seed round on April 6, 2023, led by Forerunner Ventures with participation from L Catterton, G9 Ventures, Second Sight Ventures and a group of celebrity individual investors; Forerunner's Kirsten Green joined the board at that time. Melanie Goldey serves as CEO. On April 29, 2026, Infinite Epigenetics, parent company of TruDiagnostic, announced it had acquired Tally Health's assets for an undisclosed amount, with Tally Health continuing as a standalone consumer brand under Goldey's leadership.

Risks & controversies

Product claims center on supplement benefits and reductions in epigenetic age, areas where evidence standards and regulatory scrutiny for consumer health claims apply; reported member outcome statistics are self-published by the company rather than independently verified. Company research itself notes that different epigenetic aging clocks produce divergent results and that test reproducibility varies across measurement technologies. The 2026 acquisition was an asset purchase of undisclosed value, leaving the outcome for prior investors unstated.